Pfizer’s Ponsegromab: A Promising Yet Uncertain Opportunity Influencing Hold Rating
Leerink Partners analyst David Risinger has maintained their neutral stance on PFE stock, giving a Hold rating yesterday. David Risinger has ...
BioSpace11d
Pfizer Exceeds Wall Street’s Q3 Expectations Amid Activist Investor Pressure
CEO Albert Bourla, who is under attack from activist investor Starboard Value, got a much-needed victory on Tuesday as Pfizer ...
Pfizer, Inc. (PFE) Q3 2024 Earnings Call Transcript
Q3 2024 Earnings Conference Call October 29, 2024 10:00 AM ETCompany ParticipantsFrancesca DeMartino - Chief Investor ...
pharmaphorum7d
ESMO: Pfizer drug helps cancer patients gain weight
Pfizer's anti-GDF-15 antibody ponsegromab was able to achieve weight gain in cancer patients with cachexia – a life-threatening metabolic syndrome caused by the underlying disease with no ...
Pfizer’s Activist Battle Might Fizzle—but Its Stock Probably Won’t
The pharmaceutical company’s stock is relatively cheap, representing an opportunity for patient value investors.
Pfizer (PFE) Q3 2024 Earnings Call Transcript
We had a Phase II readout of Ponsegromab, which is another in-house discovered and developed by us. We are encouraged by the ...
Investing10d
Pfizer Inc DRC (PFE)
Pfizer Inc. (NYSE:PFE) today announced its Phase 2 study of ponsegromab, a monoclonal antibody directed against growth differentiation factor-15 (GDF-15), met its primary ...